Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "Vaccine"
DOI: 10.1016/j.vaccine.2021.05.090
Abstract: A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed… read more here.
Keywords: hiv; cd4 chimeric; gp120 cd4; vaccine ... See more keywords